Octave Bioscience

Octave occupies a specialized position at the intersection of precision medicine, neurology diagnostics, and longitudinal care. Its core offering, the MSDA Test, is a commercially available blood-based assay that measures 18 protein biomarkers to quantify multiple sclerosis disease activity and translate the results into individualized clinical reports. This differentiates Octave from broad laboratory companies such as Quest Diagnostics, which is primarily a distribution and specimen-collection partner, and from traditional imaging-led MS monitoring approaches that rely heavily on MRI and clinical assessment. The company’s model also overlaps conceptually with biomarker and precision-neurology businesses, but the available company record does not identify a definitive set of direct competitors. Octave’s differentiation rests on combining multi-analyte molecular testing, machine learning, and clinical context rather than offering a single biomarker in isolation. Its platform is being extended toward progression monitoring, Parkinson’s disease, and Alzheimer’s disease, creating a broader opportunity than an MS-only test. The main market constraints are clinical adoption, reimbursement, validation across additional diseases, and the need to demonstrate that test results consistently improve treatment decisions.

Octave’s trajectory shows a transition from venture-backed platform development toward commercial scale. The company raised $2.5 million in seed financing in 2017, followed by a $14 million Series A in 2018 and a $32 million Series B in 2020. A further $32.5 million Series B was announced in 2023, alongside a $10 million Michael J. Fox Foundation grant. In September 2025, Octave recorded a $35.6 million Series C and $15.5 million debt financing, while a subsequent $10 million grant was announced in October 2025. The MSDA Test’s New York State CLEP certification on April 30, 2025 and its availability through Quest Diagnostics’ 7,000 collection sites marked important access and commercialization milestones. Website information indicates more than 29,000 patient reports and nationwide availability. During 2026, leadership additions in commercial, business development, and marketing signaled an effort to convert technical validation into broader adoption. The next growth inflection points are likely expansion beyond MS, reimbursement durability, and evidence that the platform’s progression and neurodegenerative-disease programs can achieve clinical and commercial scale.